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Abstract
 NANOG is a homeodomain-containing transcription factorBackground:
which forms one of the hubs in the pluripotency network and plays a key
role in the reprogramming of somatic cells and epiblast stem cells to naïve
pluripotency.  Studies have found that NANOG has many interacting
partners and some of these were shown to play a role in its ability to
mediate reprogramming. In this study, we set out to analyse the effect of
NANOG interactors on the reprogramming process.
 Epiblast stem cells and somatic cells were reprogrammed toMethods:
naïve pluripotency using MEK/ERK inhibitor PD0325901, GSK3β inhibitor
CHIR99021 and Leukaemia Inhibitory Factor (together termed 2i Plus LIF). 
 was knocked out using the CRISPR/Cas9 system or overexpressedZmym2
using the PiggyBac system. Reprogramming was quantified after ZMYM2
deletion or overexpression, in diverse reprogramming systems. In addition,
embryonic stem cell self renewal was quantified in differentiation assays
after ZMYM2 removal or overexpression.
 In this work, we identified ZMYM2/ZFP198, which physicallyResults:
associates with NANOG as a key negative regulator of NANOG-mediated
reprogramming of both epiblast stem cells and somatic cells. In addition,
ZMYM2 impairs the self renewal of embryonic stem cells and its
overexpression promotes differentiation.
 We propose that ZMYM2 curtails NANOG’s actions duringConclusions:
the reprogramming of both somatic cells and epiblast stem cells and
impedes embryonic stem cell self renewal, promoting differentiation.
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Introduction
Reprogramming is the process whereby a somatic cell is reverted 
back to a pluripotent state. Pluripotent cells possess the ability 
both to self-renew and to differentiate into cells from any of the 
three germ layers of the adult organism. Reprogramming can 
be carried out by overexpressing only four factors in somatic 
cells: Oct4, Klf4, Sox2 and cMyc1. Together, these factors reset 
the transcriptional and epigenetic state of the cell to those of 
a pluripotent cell. Much work has been carried out on factors 
which can execute or promote this transition. These include many 
members of the pluripotency-associated transcription factor 
network2–7. Nanog is a homeodomain-containing transcription 
factor which constitutes one of these key factors.
Nanog was first discovered for its ability to promote embry-
onic stem cell (ESC) self-renewal in the absence of LIF and for 
its association with the pluripotent state as opposed to somatic 
identities8,9. Nanog is also essential for the establishment of the 
pluripotent naïve epiblast10. Thus, Nanog plays a central role in 
the promotion of the pluripotent state, both in vitro and in vivo.
As a key hub of the pluripotency network, studies have been car-
ried out aiming at understanding Nanog’s mode of action. One 
approach was to define its interactome, which led to the identifi-
cation of multiple interactors3,11,12. Some of these are chromatin 
modifiers that were shown to augment the ability of Nanog to 
mediate reprogramming. These include the NuRD complex13 
and the TET family proteins11. Importantly, we still do not know 
if most of the identified interactors play a role, either positive 
or negative, in the mechanism of action of Nanog. In order 
to address this, we set out to analyse the effect of additional 
NANOG interactors on Nanog-mediated reprogramming. This 
work enabled us to identify ZMYM2/ZFP198, which physically 
associates with NANOG3,11,12,14, as a key protein impairing 
Nanog’s activity in both reprogramming and the self-renewal of 
naïve pluripotent stem cells.
Methods
Cell culture
Mouse ESCs, iPS cells and pre-iPS cells were cultured in 
Glasgow Minimum Essential Medium (GMEM; Sigma, G5154) 
containing 10% foetal calf serum (FCS; Life Technologies, 
10091-148), 1x non-essential amino acids solution (NEAA; PAA, 
M11-003), 1 mM sodium pyruvate (PAA, S11-003), 0.1 mM 
2-mercaptoethanol (Invitrogen 31350-010), 2mM L-glutamine 
(Invitrogen, 25030024), 1x Pen/Strep (PAA, P11010) and 20 ng/mL 
LIF (Department of Biochemistry, University of Cambridge). 
This medium will hereafter be referred to as Serum Plus LIF. 
These cells were grown on plastic dishes (Iwaki/Corning, 
10578911) which had treated with 0.1% gelatin for 10 min. 
Fibroblasts were cultured in GMEM (Sigma, G5154) containing 
10% FCS (Life Technologies, 10091-148) on gelatin-coated 
dishes.
N2B27-containing medium was made up as follows: 50% 
neurobasal (Life Technologies, 21103-049), 50% Dulbecco’s 
Modified Eagle Medium (DMEM)/F12 (Life Technologies, 
11330-057), 1X N2 (WT/MRC SCI, University of Cambridge), 
1X B27 (Life Technologies, 17504-044), 2mM L-glutamine 
(Invitrogen, 25030024), 1X Pen/Strep, 0.1 mM 2-mercaptoethanol 
(Invitrogen 31350-010).
Epiblast stem cells (EpiSCs) were cultured in N2B27-contain-
ing medium supplemented with 12.5 ng/mL FGF2 (WT/MRC 
SCI, University of Cambridge) and 20 ng/mL Activin A (WT/
MRC SCI, University of Cambridge). They were grown on 
dishes which had been coated with 10 μg/mL Human recom-
binant fibronectin (Millipore FC010) in PBS for 30 min at 
room temperature.
Neural stem cells (NSCs) were cultured in DMEM/F12 (Life 
Technologies, 11330-057) containing 27.4mM glucose, 1x NEAA 
(PAA, M11-003), 1X Pen/Strep (PAA, P11010), 4mM HEPES 
(Life Technologies, 15630-049), 0.011% Bovine serum albumin, 
1X N2 (WT/MRC SCI, University of Cambridge), 1X B27 
(Life Technologies, 17504-044), 0.1 mM 2-mercaptoethanol 
(Invitrogen 31350-010), 10 ng/mL of epidermal growth factor 
(EGF; Peprotech, 315-09) and 20 ng/mL fibroblast growth 
factor 2 (FGF2; WT/MRC SCI, University of Cambridge). They 
were cultured on plastic dishes which had been coated for at least 
3 h with 10 μg/mL laminin (Sigma, L2020) in PBS and washed 
once in PBS. 
Cell lines
Oct4 reporter EpiSCs and NSCs were used as previously detailed 
and contained an Oct4-GFP-IRES-puro reporter transgene in 
which enhanced green fluorescent protein (eGFP) is expressed 
under the control of Oct4 (Pou5f1) regulatory elements15,16. 
Nanog-GFP-IRES-puro reporter NSCs were also used as previ-
ously generated and these contained GFP inserted heterozygously 
into the AUG start codon of one endogenous Nanog allele11,17. 
Nanog-/- pre-iPSCs had been previously generated in the lab 
by the retroviral transduction of Nanog-/- NSCs isolated from 
E12.5 forebrain with Oct4, Klf4 and cMyc10 E14tg2a ESCs were 
used for all self-renewal assays18.
siRNA transfection
FlexiTube siRNA solutions (Qiagen) were used to knock down 
expression of the following genes: Zmym2 (GS76007), Zfp281 
(GS226442) and Nr0b1 (GS11614). All Star negative control 
siRNA was also used (1027281). Transfection was carried out 
with Lipofectamaine RNAi Max (Life Technologies, 13778030). 
Medium was changed to medium containing MEK/ERK 
inhibitor PD0325901, GSK3β inhibitor CHIR99021 (WT/MRC 
SCI, University of Cambridge) and Leukaemia Inhibitory Fac-
tor (Department of Biochemistry, University of Cambridge) 
(together termed 2i Plus LIF)19 with Penicillin/Streptomycin 
24 h after transfection and the cells were allowed to reprogram 
for 12 days. Green colonies, resulting from the expression of 
a Oct4-GFP reporter11,13,20, were monitored using a Leica epi-
fluorescent DMI4000 microscope at 488nm as a readout of 
reprogramming efficiency.
Measurement of pluripotency-associated gene expression 
by qPCR
Total RNA was extracted from cells using an RNeasy mini kit 
(Qiagen, 74106), with DNAse treatment (Qiagen, 79254). cDNA 
synthesis was performed using the Superscript III kit (Life 
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Technologies, 11752-250) in accordance with the manufactur-
er’s protocol. RT-qPCR was carried out in microAmp qPCR 
plates (Life Technologies, 434690) on a StepOne Plus Real-Time 
PCR machine (Applied Biosystems) using TaqMan Fast Univer-
sal MasterMix (Applied Biosystems, 4352042) and expression 
levels were calculated by ΔCt to Gapdh. Mean expression 
levels were determined by averaging triplicate wells. TaqMan 
amplification was performed as follows: 2 min at 50 °C, 20 sec 
at 95 °C, (1 sec at 95 °C, 20 sec at 60 °C) x 40. Probes used are 
presented in Table 1.
Reprogramming neural stem cells and mouse embryonic 
fibroblasts
Retroviral reprogramming vectors (pMXs-Oct4 (13366), pMXs-
Klf4 (13370), pMXs-Sox2 (13367) and pMXs-cMyc (13375)) 
were obtained from the Addgene repository. PLAT-E cells 
were transfected with these using FuGene (Promega E2311). 
The medium containing retroviral particles was collected from 
the PLAT-E cells and filtered through a 0.45 μm filter. Neural 
stem cells (NSCs) were transduced with retroviral (r) Oct4, 
cMyc and Klf4 whereas MEFs were transduced with these and 
rSox2. 4μg/ml polybrene (Sigma Aldrich, TR-1003) was added 
for transduction.
24 h after transduction, the virus-containing medium was 
aspirated from the NSCs or MEFs and replaced with the cells’ 
respective media. Four days after transduction, the medium 
was replaced with Serum-containing medium supplemented 
with Leukaemia Inhibitory Factor21 (Serum Plus LIF). The cells 
slowly became more proliferative and acquired pre-iPS cell-like 
morphology. If the pre-iPS were being reprogrammed in the same 
well, the medium was switched to medium containing MEK/
ERK inhibitor PD0325901, GSK3β inhibitor CHIR99021 (WT/
MRC SCI, University of Cambridge) and Leukaemia Inhibitory 
Factor (Department of Biochemistry, University of Cambridge) 
(together termed 2i Plus LIF)19 4 days after the application of 
Serum Plus LIF (8 days after retroviral transduction).
Cells were then stably transfected with PiggyBac (PB) Nanog 
transgenes, selected and subjected to transient transfection with 
siRNA before reprogramming in 2i Plus LIF. Oct4- or Nanog-
GFP+ colonies were counted 12 days later (see cell line section 
for details).
Zmym2 overexpression
Overexpression vectors were generated using Gateway clon-
ing (Invitrogen) and PiggyBac vectors. Cells were transfected 
using Lipofectamine 2000 (ThermoFisher Scientific 11668019) 
and selected for 14 days with either hygromycin or blasticidin 
(WT/MRC SCI, University of Cambridge).
CRISPR/Cas9 generation of Zmym2-/- EpiSC and NSC 
cells
A double-stranded break was induced 108 amino acids after the 
start codon of Zmym2, inducing frameshift mutations in both 
alleles. Pools of clones were screened by T7 assay22, which 
involves the annealing of PCR products from the edited locus to 
PCR products from the WT locus. These double stranded frag-
ments are then digested with T7 endonuclease, which cuts the 
imperfectly annealed strands. These cut products can then be 
visualised using agarose gel electrophoresis. Single transfected 
cells were then sorted and analysed for ZMYM2 knockout by 
Western Blotting (see Table 2 for antibodies used). Clones 
were selected which had no intact Zmym2 alleles and were 
stably transfected with Nanog or Zmym2 transgenes or both, or 
their corresponding empty vector transgenes.
Antibodies
Self-renewal assay for ESCs. Zmym2 was stably overexpressed 
in ESCs or knocked out by CRISPR/Cas9 as detailed above. 
These cells were plated alongside Empty Vector (EV) controls 
in Serum-containing medium with or without LIF for 6 days. 
Alkaline-phosphatase staining (Sigma, 86R-1KT) was carried 
out and colonies were scored by both morphology and alkaline 
phosphatase staining.
Table 1. Probes used for qPCR.
Probe Applied Biosystems ID
Klf4 Mm00516104_m1
Klf2 Mm01244979_g1
Rex1 Mm03053975_g1
Nr0b1 Mm00431729_m1
Oct4 Mm00658129_gH
Zmym2 Mm00813221_m1
Esrrb Mm00442411_m1
Nanog Mm02384862_g1
Gapdh Mm99999915_g1
Table 2. Antibodies used for western blots.
Target Species Clonality Concentration Dilution Cat no Supplier
alpha tubulin mouse Mono 1 mg/mL 1:5000 ab7291 Abcam 
NANOG rat Mono 500 μg/mL 1:100 eBio MLC51 eBiosciences 
OCT4 C10 mouse Mono 200 μg/mL 1:500 sc-5279 Santa Cruz 
ZMYM2 rabbit Poly 400 μg/mL 1:440 ab30783 Abcam 
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Transcriptome analysis
mRNA was extracted with a RNeasy kit (Qiagen, 74106), with 
DNAse treatment (Qiagen, 79254). It was quantified using Agi-
lent Bioanalyzer Nano Chips (Agilent Technologies). Deple-
tion of ribosomal RNA was performed on 2-5 μg of total RNA 
using the Ribo-Zero rRNA Removal Kit (Illumina) and libraries 
were produced from 10-100ng of ribosomal-depleted RNA 
using NextFlex Rapid Directional RNA-seq Kit (5138-07; 
Bioo Scientific), a Biorad C1000 thermocycler, and standard 
Illumina primers. Cycling conditions were as follows: 30 min 
at 37°C, 2 min at 98°C, (30 sec at 98°C, 30 sec at 65°C, 60 sec 
at 72°C) x 12, 4 min at 72°C. Libraries were pooled in equi-
molar quantities and sequenced on the HiSeq4000 platform 
(Illumina), using V4 chemistry.
RNA-seq reads were adaptor-trimmed with TrimGalore (ver-
sion 0.3.7) and mapped to the mouse reference genome 
(GRCm38/mm10) with TopHat2 (version 2.2.3). Strand-specific 
read counts were obtained with featureCounts (version 1.4.5). 
Transcript counts were normalised, and the statistical significance 
of differential expression between samples was assessed using 
the R Bioconductor DESeq2 (version 1.4.5) package. Transcript 
counts normalized by DESeq2 size factors were subsequently 
normalized by their length.
Blastocyst injection and animal husbandry
Chimeras were generated from mouse strain 129 (agouti coat 
color) iPSCs by standard microinjection methodology at the 
Wellcome Trust/MRC Cambridge Stem Cell Institute. Briefly, 
host blastocysts of strain C57BL/6 (black coat colour) were 
injected at E4.5, followed by gestation in pseudo-pregnant recipi-
ent females23. These females were 6–10 weeks old and 25–30g. 
The resulting chimeras were then bred with WT mice and the 
pups analysed by coat colour for contribution of the iPS-derived 
cells. The use of animals in this project was approved by 
the Animal Welfare and Ethical Review Body for the University 
of Cambridge (Procedure Project Licenses P76777883 and 
80/2597). Mice were housed in individual ventilated cages 
with up to 5 animals per cage. Stud males were individually 
caged and females were housed in groups, with wood chips 
and mouse bedding plugs on the cage floor. The mouse facility 
was a barrier facility with 10 hours darkness and 14 hours light 
per day. The temperature was maintained at 22 °C. Food and 
water were provided ad libitum. Cages contained environ-
mental enrichment for the mice, including wooden blocks and 
perspex houses. All animals were checked on a daily basis 
by trained animal house staff, but there are no welfare issues 
expected from the embryo transfer procedure, which is performed 
routinely by the dedicated transgenic facility manager. Every 
effort was made to reduce the numbers of animals used and the 
stress or discomfort caused to animals in this study. The final assay 
result is coat colour of the pups, and did not involve any inva-
sive or stressful procedures. Further details regarding the mice 
used are presented in Table 3.
Results
Zmym2 impairs Nanog -mediated reprogramming in EpiSCs
In this study, we aimed to characterise potential regulators of 
Nanog’s activity during reprogramming. We compared NANOG 
interactomes3,11,12 and selected ZMYM2 and NR0B1 as candi-
dates of interest due to these being high confidence interactors. 
ZFP281 was selected as a control, as knocking it down had been 
previously demonstrated to increase Nanog-mediated repro-
gramming efficiency24. In order to address whether these factors 
impact Nanog-induced reprogramming, Nanog-overexpressing 
EpiSCs, which reprogram at low efficiency10,20, were transiently 
transfected with siRNA against the target genes of interest 
(Figure 1A). The medium was then swapped to medium contain-
ing the MEK/ERK inhibitor PD0325901 and the GSK3β inhibi-
tor CHIR9902119. This medium will hereafter be referred to 
as (2i) plus LIF medium (2i Plus LIF). This medium promotes 
reprogramming19. These cells express enhanced green fluorescent 
protein (eGFP), under the control of Oct4 (Pou5f1) regulatory 
elements, making the cells GFP+ when fully reprogrammed 
to naïve pluripotency15,16. As a readout of reprogramming 
efficiency, Oct4-GFP+ colonies were counted 12 days after 
the application of 2i Plus LIF. 
Nr0b1 knockdown (KD) did not alter reprogramming efficiency. 
Zfp281KD increased Nanog mediated reprogramming efficiency, 
consistent with a previous report24. Interestingly, reprogramming 
efficiency was robustly increased by Zmym2KD (Figure 1A). 
Zmym2 transcript and protein levels were reduced by all four 
siRNAs by qPCR and by Western blot (Figure 1B and 1C 
respectively), 48h after transfection. This contrasts with the 
action of many other NANOG interactors as activators of 
reprogramming11,13 and suggests that Zmym2 impedes Nanog- 
mediated reprogramming. The iPSCs generated after Zmym2KD 
were characterised and had gene expression profiles consistent 
with the acquisition of naive pluripotency (Figure 1D) and 
upon injection into C57Bl6 mouse host blastocysts, chimerae 
were produced (Figure 1E). Zmym2KD iPSCs also exhibited 
germline competence (Figure 1F). This indicates faithful iPSC 
reprogramming following Zmym2KD.
Table 3. Details of mice used for chimera contribution assay. Zmym2 KD or OE iPSCs were injected into E4.5 C57Bl6 host 
blastocysts. The resulting embryos were implanted into pseudopregnant females and the pups analysed for iPS contribution by coat 
colour. M:male, F:female, GLT: germline transmission.
Contribution
Date Clone 
name
No. of 
Females
Strain No. of 
embryos
No. 
injected
No. 
transferred
No. 
recipients
No. 
pregnant
No. 
born
No. of 
chimeras
M F high medium Low GLT
13/05/2013 Zmym2 
KD
12 C57Bl6 74 70 70 5x25 2 17 5 3 2 0 5 0 Yes
14/06/2013 Zmym2 
OE
9 C57Bl6 21 20 20 2x25 1 2 0 0 0 0 0 0 N/A
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Figure 1. Zmym2 is a repressor of Nanog-mediated epiblast stem cell (EpiSC) reprogramming. a, 2000 EpiSCs were transiently transfected 
with siRNA against the indicated targets and reprogrammed by Nanog overexpression in 2i Plus LIF. Oct4-GFP+ colonies were scored on 
day 12. Data represent the mean number of Oct4-GFP+ colonies from two replicates +/- SEM. Example colonies are shown in the inset panel. 
b, RT-qPCR analysis of EpiSC lines 48h after Zmym2KD. Data are the mean normalized expression level from 3 technical replicates +/- SD. 
c, Western Blot of EpiSC lines 48h after Zmym2KD with alpha tubulin shown as a loading control. d, Gene expression analysis of the parent 
EpiSCs and resulting iPSCs by qPCR. Data are the mean normalised expression levels from 3 technical replicates +/- SD. e, iPSCs which 
emerged from Zmym2KD EpiSCs were injected into C57Bl6 blastocysts to generate chimeras, which can be seen from their coat colour 
(brown fur conferred by iPSC contribution). f, Germline transmission of the iPSCs (brown pup from iPSCs shown with its chimera mother and 
black father). g, Western Blot of lines of empty vector (EV) and NANOG-overexpressing (Nanog) EpiSCs with alpha tubulin shown as a loading 
control. h, GFP+ colony count of EV- and Nanog-overexpressing EpiSCs when reprogrammed in the presence of siRNA against Zmym2 or 
control siRNA. Data represent the mean +/- SEM of two independent experiments.
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Given that these EpiSCs overexpressed Nanog to promote repro-
gramming, we then investigated whether Zmym2KD is sufficient 
to reprogram EpiSCs in the absence of any transgenic repro-
gramming factors. In order to address this, EpiSCs overexpress-
ing Nanog or a corresponding empty vector (EV) transgene 
(Figure 1G) were transfected with siRNA against Zmym2 and 
transferred to reprogramming conditions. Zmym2KD had a pro-
nounced positive effect on Nanog-induced reprogramming but a 
minimal effect on the reprogramming of EV EpiSCs (Figure 1H). 
Therefore, Zmym2KD relies on the exogenous expression of Nanog 
in order to robustly enhance reprogramming.
Zmym2 impairs Nanog -mediated somatic cell 
reprogramming
All experiments described so far had been carried out in EpiSCs. 
We used reprogramming intermediates generated from neural 
stem cells (NSCs) through retroviral expression of Oct4, Klf4 and 
cMyc, to address whether Zmym2 might also inhibit Nanog-induced 
reprogramming in a somatic cell context. These cells were stably 
transfected with a PiggyBac (PB) Nanog transgene and subjected 
to transient transfection with either control or Zmym2 siRNA. In 
keeping with the results obtained in EpiSCs, Zmym2KD increased 
somatic cell reprogramming more than two-fold (Figure 2A). 
To ascertain whether Zmym2KD could reprogram somatic cells 
in the absence of Nanog, the same experiment was carried out in 
Nanog-/- somatic cells10.  These were stably transfected with a res-
cue Nanog transgene or a corresponding EV transgene, and repro-
grammed after control KD or Zmym2KD. As seen in Figure 2B, 
Zmym2KD also enhanced Nanog-mediated reprogramming in 
neural stem cell derived reprogramming intermediates. Zmym2KD 
was not sufficient to overcome the requirement for Nanog in 
somatic cell reprogramming, though we confirmed that it enhances 
Nanog-mediated reprogramming in this context.
As Zmym2KD increases Nanog-mediated reprogramming effi-
ciency, we decided to carry out the converse experiment and 
investigate whether Zmym2 overexpression could impair repro-
gramming. Four lines of EpiSCs were generated which stably 
overexpressed either Nanog, Zmym2, or both (Figure 2C), 
and these were induced to reprogram by transfer to 2i Plus LIF 
medium. As expected, Nanog overexpression resulted in efficient 
EpiSC reprogramming while Zmym2 overexpression alone had 
no reprogramming activity (Figure 2D). However, when Zmym2 
overexpression was combined with Nanog overexpression, it 
reduced reprogramming efficiency 8-fold relative to Nanog alone 
(Figure 2D). To test this result in an independent cell system 
mouse embryonic fibroblast (MEF)-derived reprogramming 
intermediates expressing retroviral Oct4, Klf4, cMyc and Sox2 
and a Nanog transgene were transfected with either Empty 
Vector (EV) or a Zmym2 expression cassette (Figure 2E). 
Nanog alone led to highly efficient complete reprogramming 
(Figure 2F, G, H) whereas the addition of Zmym2 completely 
prevented reprogramming.
In order to investigate the effect of Zmym2 loss in reprogram-
ming, Zmym2-/- EpiSCs were generated by CRISPR/Cas9-mediated 
mutagenesis (Figure 3A). WT and Zmym2-/- EpiSCs were then 
stably transfected with Nanog or Zmym2 or both (Figure 3A) 
and allowed to reprogram. Similar to previous results, Zmym2 
overexpression decreased Nanog-mediated reprogramming in 
wild type cells (Figure 3B). In agreement with KD experiments, 
Zmym2 knockout increased Nanog-induced reprogramming 
by about 4-fold (Figure 3B). This effect was rescued by the 
addition of transgenic Zmym2 (Figure 3B). WT and Zmym2-/- 
iPSCs were indistinguishable by gene expression analysis 
of pluripotency-associated markers (Figure 3C).
To verify this result in an independent cell system, WT or 
Zmym2-/- NSCs were also generated by CRISPR/Cas9-mediated 
mutagenesis (Figure 3D). They were then retrovirally transduced 
with Oct4, Klf4 and cMyc and allowed to reprogram. As in EpiSCs, 
Zmym2-/- NSCs reprogrammed with much higher efficiency than 
their WT counterparts (Figure 3E, F). Both WT and Zmym2-/- 
iPSCs had gene expression profiles similar to those of control 
ESCs, demonstrating complete reprogramming (Figure 3G). 
Both WT and Zmym2-/- NSC lines were then stably trans-
fected with Nanog, Zmym2, or both, to create a rescue system 
for reprogramming (Figure 3D). Again, Zmym2 knockout increased 
Nanog-induced reprogramming by 3-fold (Figure 3H), whereas 
its overexpression eliminated the enhancement of reprogramming 
by Nanog (Figure 3H).
Zmym2 reduces ESC self-renewal
Zfp281 is known to enable Nanog autorepression24 so we tested 
whether Zmym2 levels had any effect on Nanog transcript levels. 
Neither KD nor overexpression lines had any change in Nanog 
transcript or protein levels (Figure 1B, 1C, Figure 2C, 
Figure 3C, 3G), suggesting that Zmym2 does not act through the 
regulation of Nanog expression.
Nanog was first discovered for its role in the self-renewal of 
ESCs8,9. As ZMYM2 is a NANOG interactor, we hypothesised 
that it might also inhibit Nanog’s self-renewal-promoting 
capacity. In order to address this, Zmym2 was stably trans-
fected into ESCs. These cells were plated alongside EV controls 
(Figure 4A) in Serum-containing medium with LIF for 6 
days, to maintain pluripotency in some cells while allowing 
others to differentiate. Alkaline-phosphatase staining was carried 
out and colonies were scored. Zmym2-overexpressing ESCs 
exhibited greater spontaneous differentiation than control ESCs 
(Figure 4B, C).
In order to investigate whether Zmym2KO impedes ESC dif-
ferentiation, both Zmym2 alleles were knocked out using the 
CRISPR/Cas9 system as previously described. ZMYM2-/- cells and 
FLAG-tagged Zmym2 rescue cells were generated (Figure 4D). 
These lines were plated alongside the parental WT ESC line in 
the absence of LIF for 6 days, alkaline phosphatase stained and 
colonies were scored by morphology. Zmym2KO increased 
the proportion of undifferentiated colonies (Figure 4E). This was 
rescued by transgenic Zmym2 expression. This is in agreement 
with a recently published Cas9 ESC differentiation screen which 
demonstrated that Zmym2KO ESCs resist differentiation25.
To address the global effects of Zmym2 loss on the transcrip-
tome, mRNA from Zmym2 KO, WT and overexpressing ESCs 
(Figure 5A, B) were subjected to mRNA-Seq after culture in 
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Figure 2. Zmym2 inhibits somatic cell reprogramming in a Nanog-dependent manner. a, Neural stem cells (NSCs) were reprogrammed 
with retroviral Oct4, Klf4 and cMyc and with constitutive transgenic Nanog expression in 2i Plus LIF in the presence of Zmym2 or control 
siRNA. Colony count per 75,000 plates NSCs. Average of three independent experiments. **** p<0.0005 by Student’s T-test. b, Average 
GFP+ colony count per 10,000 Nanog-/- pre-iPSCs reprogrammed in the presence of Zmym2 or control KD, two replicates +/-SEM c, Gene 
expression analysis of EpiSC lines stably overexpressing Nanog, Zmym2, or both by RT-qPCR. d, Average GFP+ colony count on D12 after 
2i Plus LIF application per 25,000 plated EpiSCs, three replicates. e, Gene expression analysis by qPCR of MEF-derived pre-iPSCs stably 
overexpressing Nanog+EV or Nanog+Zmym2, with ESC control. f, Fluorescence and brightfield images of Oct4-GFP+ colonies on D12 g, 
Average GFP+ colony count on D12 per 50,000 plates pre-iPSCs, three replicates. h, Alkaline phosphatase staining on D12. Reprogramming 
counts are shown as mean +/-SEM. qPCR quantifications are shown as mean of three technical replicates +/- SD, normalised to GAPDH 
transcript levels.
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Figure 3. Zmym2 knockout enhances Nanog-mediated reprogramming in epiblast stem cells (EpiSCs) and somatic cells. a,Western blot 
analysis of starting populations of EpiSCs. Both alleles of Zmym2 were disrupted with the CRISPR/Cas9 system. Nanog, Zmym2 or both were 
stably overexpressed. b, Average GFP+ colony count of reprogrammed EpiSCs on D12 for Zmym2-/- and WT EpiSCs, per 50,000 cells plated, 
three replicates. c, Gene expression analysis of the resulting iPSCs shows them to be faithfully reprogrammed, in contrast to the starting 
population of EpiSCs. d, Western blot analysis of starting populations of NSCs. Both alleles of Zmym2 were disrupted with the CRISPR/Cas9 
system. Nanog, Zmym2 or both were stably overexpressed. Clustal Omega multiple sequence alignment of KO clones with the WT sequence 
and reverse complement sequencing traces of Zmym2KO EpiSCs and NSCs. e, Average iPSC colony count after reprogramming of Zmym2-/- 
and WT NSCs per 75,000 cells plated. f, Fluorescence and brightfield images of iPSCs generated from Zmym2-/- and WT NSCs after retroviral 
Oct4, Klf4 and cMyc overexpression and exposure to 2i Plus LIF. Scale bar 500μm. g, Gene expression analysis of the resulting WT and 
Zmym2-/- iPSCs by qPCR. h, NSCs were stably transfected with Nanog, Zmym2 or both and reprogrammed with retroviral Oct4, Klf4 and cMyc 
in 2i Plus LIF. Average colony count for Zmym2-/- and WT NSCs per 75,000 cells plated, three replicates. Reprogramming counts are shown as 
mean +/- SEM. qPCR quantifications are shown as mean of three technical replicates +/- SD, normalised to Gapdh transcript levels.
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Figure 4. Zmym2 inhibits embryonic stem cell (ESC) self-renewal. a, Western blot analysis of ESCs stably overexpressing Zmym2 or a 
corresponding EV transgene. b, Brightfield images of alkaline phosphatase stained plates of EV- of Zmym2-overexpressing ESCs after 6 days 
in medium containing either serum or Serum+LIF. Scale bar 500μm. c, Scores of undifferentiated colonies on D6 after plating in Serum or 
Serum Plus LIF. Mean of 3 replicates +/-SEM. d, Zmym2 was disrupted using CRISPR/Cas9. Clones were stably transfected with Zmym2 or a 
corresponding EV transgene. Western blot of two resulting ESC clones; the knockout clone was sequenced and used for further experiments. 
e, Scores of undifferentiated colonies on D6 after plating WT, Zmym2-/- and Zmym2 rescued lines in Serum or Serum Plus LIF indicate that 
Zmym2 deletion may impede differentiation in the absence of LIF. Mean of 3 replicates +/- SEM.
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Figure 5. Zmym2 overexpression correlates with the mis-expression of early lineage markers. a,Brightfield images of Cas9-generated 
Zmym2-/- (Figure 4D), WT and Zmym2 overexpressing embryonic stem cells (ESC) in Serum Plus LIF-containing medium. b, Western blot 
analysis of these ESC lines. c, RNA Seq analysis was performed on the lines shows an upregulation in the transcript levels of early lineage 
specifiers of trophectoderm (TE), ectoderm and EpiSCs (EpiSCs/Ecto), mesoderm (meso) and endoderm (endo) and a corresponding 
decrease in the transcript levels of inner cell mass (ICM) markers in Zmym2 overexpressing ESCs. Conversely, Zmym2-/- ESCs have lower 
transcript levels of early lineage markers.
Serum Plus LIF-containing medium. Zmym2 overexpressing 
cells had higher transcript levels of many lineage specifiers 
than control cells including early ectodermal, mesodermal and 
endodermal markers, as well as trophectodermal markers, after 
normalisation to housekeeping genes. In addition, they had 
reduced transcript levels of a number of pluripotency-associated 
genes. Conversely, Zmym2KO cells had reduced expression of 
differentiation markers. In conclusion, Zmym2 inhibits repro-
gramming and promotes differentiation. It has a global 
effect on the transcriptome of ESCs, increasing the transcription 
of differentiation-associated genes and reducing pluripotency- 
associated transcripts. 
Discussion
In this work, we show that Zmym2 represents a significant 
barrier to Nanog-mediated reprogramming. We observed con-
sistent results using gain and loss of function assays in many 
different reprogramming systems, including EpiSCs, fibrob-
lasts and neural stem cells. This corroborates results obtained by 
other groups working on RNAi in human cell reprogramming26. 
Therefore, ZMYM2 may play a similar role in the control of 
NANOG in mouse and human.
We also observe that Zmym2 promotes embryonic stem cell 
differentiation. This has also been reported in a Cas9 screen for 
differentiation-promoting factors25. Future work could examine 
whether the absence of Zmym2 impacts mouse development 
and elucidate its role in vivo.
In conclusion, this work has elucidated the key role of Zmym2 
as a barrier to reprogramming and a differentiation-promoting 
transcription factor. This is particularly interesting as many pre-
vious studies of Nanog’s mechanism of action have identified 
positive regulators of its activity11,13. We have shown both more 
effective reprogramming and less differentiation upon removal 
of Zmym2 demonstrating how the tight control of NANOG by 
its binding partners exerts a directive influence on cell identity 
transitions, both entering and exiting the pluripotent  state. 
Data availability
Underlying data
RNASeq data from WT, Zmym2 knockout- and Zmym2 
overexpressing- E14tg2a mouse embryonic stem cells, Accession 
number GSE130317: http://identifiers.org/geo:GSE130317
Open Science Framework: ZMYM2. https://doi.org/10.17605/OSF.
IO/TFKHR27
This project contains the following underlying data:
•    1c.pdf (x-ray films for Western blot in Figure 1c)
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•    1g.jpg (x-ray films for Western blot in Figure 1g)
•    2h.jpg (alkaline phosphatase staining for colony counts 
in Figure 2h)
•    3a d 5b.pdf (x-ray films for Western blot in Figure 3a, 3d 
and Figure 5b)
•    3f_1.tif (Image taken at 488nm of Oct4-GFP+ colonies 
for Figure 3f)
•    3f_2.tif (Brightfield image of Oct4-GFP+ colonies 
shown in 3f-1)
•    3f_3.tif (Image taken at 488nm of Oct4-GFP+ colonies 
for Figure 3f)
•    3f_4.tif (Brightfield image of Oct4-GFP+ colonies 
shown in 3f-3)
•    4a.pdf (x-ray films for Western blot in Figure 4a)
•    4b_1.tif (Brightfield image of alkaline phosphatase-stained 
well shown in 4b)
•    4b_2.tif (Brightfield image of alkaline phosphatase-stained 
well shown in 4b)
•    4b_3.tif (Brightfield image of alkaline phosphatase-stained 
well shown in 4b)
•    4b_4.tif (Brightfield image of alkaline phosphatase-stained 
well shown in 4b)
•    4c_1.jpg (alkaline phosphatase staining for colony 
counts in Figure 4c)
•    4c_2.jpg (Coomassie staining for colony counts in 
Figure 4c)
•    4c_3.jpg (alkaline phosphatase staining for colony counts 
in Figure 4c)
•    4c_4.jpg (Coomassie staining for colony counts in 
Figure 4c)
•    4d_1.pdf (x-ray films for Western blot in Figure 4d)
•    5a KO ESCs.jpg (Brightfield image of KO ESCs shown 
in 5a)
•    5a WT ESCs.jpg (Brightfield image of WT ESCs shown in 
5a)
•    5a Zfp198BSD E14.jpg (Brightfield image of OE ESCs 
shown in 5a)
•    All data Zmym2 Lawrence.xlsx (All GFP+ colony 
counts, Coomassie colony counts, alkaline phosphatase+ 
colony counts, and qPCR Ct values underlying this paper)
•    CC0: Results.pdf (PDF confirming that these results 
have been declared CC0)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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I think this is a very good and interesting paper that addresses an important issue in stem cell biology.
Some years ago, NANOG was identified as a “gateway to pluripotency”, so how its activity is regulated
during reprogramming is of considerable interest. Here the authors investigate the activity of a
transcription factor called ZMYM2 that they have identified as a component of the NANOG interactome,
and they show that it inhibits NANOG activity both during reprogramming and self-renewal. Other studies,
including work by the same lab, have demonstrated the augmentation of NANOG activity by components
of the interactome; this is the first to my knowledge to show an inhibitory activity. Interestingly, ZMYM2
does not inhibit NANOG expression, so its effects must be biochemical, and future studies to elucidate
these biochemical activities will also be of considerable interest in the field. The studies are thorough, well
executed and convincing. For example, the authors use several different reprogramming contexts,
including epiSC, fibroblasts and neural stem cells to demonstrate the inhibitory effects of ZMYM2 on
reprogramming. They also use a combination of knockout and overexpression experiments, which clearly
demonstrate complementary results that reinforce the paper’s conclusions. Their data also show that
ZMYM2 inhibits self-renewal by promoting differentiation, suggesting it may play an interesting role in
cell-specification  . In all this paper is certainly worthy of indexing and it will be of interest to the field.in vivo
I think a couple of minor issues should be addressed.
First, the second line of the Introduction states that pluripotent cells possess the ability to self-renew.
However, this is only true of pluripotent stem cells maintained in culture. The pluripotent cells in an
embryo do not necessarily self-renew, particularly in non-mammalian systems where the number of
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 embryo do not necessarily self-renew, particularly in non-mammalian systems where the number of
pluripotent cells increases by cleavage rather than expansion of an epiblast.
In Figure 4d the difference between the mutant and a knockout ESC lines should be made clearer. The
different patterns of ZMYM2 in the two lines should also be explained in the text.
Figure 4e does not show ESC in serum plus LIF.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
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